Complement C1s inhibitors - Pipeline Insight, 2024

This “ Complement C1s inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Complement C1s inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Complement C1s inhibitors Understanding

Complement C1s inhibitors: Overview

C1 inhibitor is a broad-spectrum serpin that inhibits the activated forms of several members of the complement pathway (C1r and C1s), the contact system (FXIIa, FXIa, and kallikrein) as well as fibrinolytic proteases (plasmin, t PA and uPA). C1-INH binds covalently to C1r and C1s, leading to dissociation of the C1 macromolecular complex and inhibition of the enzymatic actions of C1r and C1s. Several C1 inhibitors targeting C1s are progressing towards clinicaltrials.

Complement C1s inhibitors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complement C1s inhibitors pipeline landscape is provided which includes the disease overview and Complement C1s inhibitors treatment guidelines. The assessment part of the report embraces, in depth Complement C1s inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complement C1s inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Complement C1s inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Complement C1s inhibitors.

Complement C1s inhibitors Emerging Drugs Chapters

This segment of the Complement C1s inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Complement C1s inhibitors Emerging Drugs

Sutimlimab: Bioverativ Sutimlimab, formerly known as BIVV009 or TNT009, is an investigational monoclonal antibody that causes selective blockade of complement C1, a protein with an integral role in the classical complement pathway. This pathway is overactivated in cold agglutinin disease (CAD). By blocking C1, sutimlimab treats the underlying cause of hemolysis, thus preventing hemolytic anemia and reducing the disease burden. The U.S. Food and Drug Administration (FDA) has issued a complete response to Sanofi’s application requesting that its investigational therapy sutimlimab be approved for treating hemolysis - the breakdown of red blood cells - in adults with cold agglutinin disease (CAD). The U.S. Food and Drug Administration (FDA) has issued a complete response to Sanofi’s application requesting that its investigational therapy sutimlimab be approved for treating hemolysis - the breakdown of red blood cells - in adults with cold agglutinin disease (CAD). While the complete response letter did not report any issues regarding clinical data on the therapy’s safety and effectiveness, which were provided in Sanofi’s biologics license application, it referred to “certain deficiencies” detected by the agency during a pre-license inspection of a third-party manufacturingfacility.

Complement C1s inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Complement C1s inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Complement C1s inhibitors

There are approx. 4+ key companies which are developing the therapies for Complement C1s inhibitors. The companies which have their Complement C1s inhibitors drug candidates in the most advanced stage, i.e. preregistration include Bioverativ.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Complement C1s inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Complement C1s inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complement C1s inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complement C1s inhibitors drugs.

Complement C1s inhibitors Report Insights

• Complement C1s inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Complement C1s inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Complement C1s inhibitors drugs?
• How many Complement C1s inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complement C1s inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Complement C1s inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Complement C1s inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.